drugset / Trial / NCT00752947
Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether moxifloxacin in comparison to levofloxacin plus metronidazole are effective and safe in the treatment of community-acquired pneumonia with aspiration factors.
Timeline
- Start
- 2008-09
- Primary completion
- 2010-03
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Levofloxacin | Small molecule | 400 mg | Intravenous |
| Comparator | Metronidazole | Small molecule | 0.2 g | Intravenous |
| Subject | Moxifloxacin | Small molecule | 400 mg | Intravenous |